3M
Solventum (formerly 3M Health Care) designs and manufactures 3M™ Membrana™ capillary membranes from engineered polymers for OEM integration into medical devices for blood oxygenation, hemodialysis, and therapeutic apheresis.
- Company typePrivate
- Founded2024
- Headquarters—
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What 3M does
Solventum, operating the legacy 3M™ Membrana™ medical membrane materials franchise, designs and manufactures specialized capillary membranes from engineered synthetic polymers for integration into medical devices. Its product portfolio spans three primary clinical use cases: blood oxygenation in cardiac surgery and extracorporeal support (OXYPLUS™, OXYPHAN™, X30, HEXPET™), hemodialysis and hemodiafiltration (DIAPES™, PUREMA™, SYNPHAN™), and therapeutic apheresis and plasma fractionation (SYNCLEAR™, MicroPES™ TF10, PLASMAPHAN™, FractioPES™). Each membrane family is engineered with specific pore structures — including asymmetric, sponge-like, and thermally induced phase separation polypropylene architectures — to deliver defined sieving coefficients, biocompatibility, and endotoxin barrier performance tailored to OEM device requirements. Capabilities include customer-specific membrane manufacturing alongside standard product lines.
The business operates a pure OEM/embedded B2B go-to-market, selling membrane materials directly to medical device manufacturers and integrators rather than to end clinical customers. GTM is quote-based via an 'Ask an expert' inquiry form that segments inquiries by OEM/integrator, distributor, end user, or engineering firm, supplemented by an authorized distributor network and a technical resources library of product data sheets and ISO certificates. Pricing is not publicly disclosed. The unit serves global medical device OEMs across more than 35 countries in North America, LATAM, Europe, APAC, the Middle East, and Africa.
Ownership has undergone two consecutive restructurings in an 18-month window. The business originated inside 3M's Health Care segment, was spun off into Solventum in 2024, and the broader Purification and Filtration Business — including these medical membrane materials — was acquired by Thermo Fisher Scientific in 2025. The Wuppertal, Germany facility associated with the Membrana brand employs approximately 120 people.
3M firmographics
Firmographics- Name
- 3M
- Legal name
- Solventum
- Website
- https://membrana.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Solventum (formerly 3M Health Care) designs and manufactures 3M™ Membrana™ capillary membranes from engineered polymers for OEM integration into medical devices for blood oxygenation, hemodialysis, and therapeutic apheresis.
- Ownership category
- akta.pro rank
3M business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales
Revenue model
- Medical Membrane Materials Sales to OEMs: Sale of specialized capillary membranes to medical device manufacturers (OEMs/integrators) for integration into their medical devices for blood oxygenation, hemodialysis, and therapeutic apheresis applications. The Purification and Filtration Business (including medical membranes) has been acquired by Thermo Fisher Scientific as of 2025.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
3M product offering
Product offeringCore offering
3M (Membrana division, now part of Solventum / acquired by Thermo Fisher Scientific in 2025) manufactures and sells specialized capillary membranes under the 3M™ Membrana™ brand for OEM integration into medical devices. The portfolio spans blood oxygenation membranes for cardiac surgery and respiratory therapies, hemodialysis membranes for blood purification, and therapeutic apheresis membranes for plasma separation and fractionation. Products are engineered from synthetic polymers with tailored separation profiles, biocompatibility, and chemical resistance for extracorporeal blood processing devices.
Product overview
Solventum's Medical Membrane Materials portfolio comprises specialized capillary membranes designed for OEM integration into medical devices. The product line spans three primary therapeutic applications: blood oxygenation (including OXYPLUS, OXYPHAN, and X30 capillary membranes for cardiac surgery and respiratory therapies), hemodialysis and blood purification (including DIAPES, PUREMA, and SYNPHAN capillary membranes), and therapeutic apheresis (including SYNCLEAR, MicroPES, PLASMAPHAN, and FractioPES capillary membranes). These membranes serve as critical components in extracorporeal blood processing devices, enabling separation of blood components while maintaining biocompatibility and clinical efficacy. The company also offers customer-specific membrane manufacturing capabilities alongside standard product lines.
Differentiator
Problem solved
Functional benefit
Brands
- 3M™ Membrana™: Medical membrane materials brand for blood oxygenation, hemodialysis, and therapeutic apheresis applications. Products include OXYPLUS, OXYPHAN, PUREMA, DIAPES, SYNPHAN, MicroPES, PLASMAPHAN, SYNCLEAR, and FractioPES capillary membranes.
- Clarity™
- Solventum™ Fluency™
- Solventum™ Cloud Platform
- Solventum™ 360 Encompass™ System
- Littmann®
Companies that use 3M
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
3M technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature11 records
3M partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Thermo Fisher ScientificflagshipThermo Fisher Scientific completed the acquisition of Solventum's Purification and Filtration Business in 2025. This includes the medical membrane materials business previously part of 3M's Health Care segment. The acquisition integrates Solventum's membrane technology portfolio for biopharmaceutical purification, manufacturing, and OEM applications into Thermo Fisher Scientific's offerings.
Recent moves4 records
Expansion highlights5 records
3M competitors and assessment
Company assessmentBroad incumbents
- Fresenius Medical Care: Fresenius Medical Care is the world's largest dialysis products and services company, producing dialyzers, dialysis machines, and related consumables. Relevant peer as a vertically integrated buyer and producer of dialysis membranes and a potential OEM customer.
- Nipro Corporation: Nipro manufactures dialyzers and other medical devices, including dialysis membranes. Comparable as a producer of hollow-fiber dialysis membranes and a competitor/supplier in the OEM capillary membrane market.
- Terumo Corporation: Terumo manufactures blood component collection and therapeutic apheresis devices, and is a major participant in the extracorporeal blood processing market. Comparable as an OEM device customer/competitor in apheresis and oxygenation devices.
- Baxter International: Baxter manufactures dialysis machines and related renal care products, and historically has been a major OEM-level participant in extracorporeal blood purification. Comparable as a buyer/integrator of membrane technology in dialysis and apheresis.
- Medtronic: Medtronic offers cardiac surgery and perfusion products and is a broad incumbent in medical devices serving similar procedural end markets (cardiac surgery, oxygenation). Comparable as a downstream device manufacturer that sources capillary membranes.
- B. Braun Avitum: B. Braun's Avitum division produces dialyzers and dialysis equipment, sourcing or producing its own hollow-fiber membranes. Relevant comparable as another vertically integrated dialysis player serving similar clinical end markets.
Direct peers
- Toray Industries (Medical Division): Toray produces hollow-fiber membranes for hemodialysis, hemodiafiltration, and other extracorporeal blood purification applications. Directly competes with 3M Membrana in supplying medical-grade capillary membranes to device OEMs.
- Asahi Kasei Medical: Asahi Kasei Medical is a leading global manufacturer of hollow-fiber membranes for artificial kidneys (dialyzers), therapeutic apheresis, and related blood-purification devices. Directly comparable to 3M Membrana as a supplier of specialty capillary membranes to medical device OEMs in dialysis and apheresis.
Emerging players
- Cytiva (Danaher): Cytiva, now part of Danaher, supplies filtration and purification consumables for biopharmaceutical manufacturing. Comparable as an adjacent membrane/filtration specialist and as a sibling unit under the same acquirer (Thermo Fisher operates in adjacent bioprocessing spaces).
- Sartorius AG: Sartorius supplies filtration and membrane-based products for bioprocessing, an adjacent application of hollow-fiber technology. Comparable as a membrane science specialist expanding into adjacent medical/bioprocessing use cases.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
3M social profiles
Digital presence3M financial estimates
Financial estimateRevenue estimate
Valuation estimate
3M leadership team
Management profileNumber of profiles
3M funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
3M M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 3M
What does 3M do?
3M (Membrana division, now part of Solventum / acquired by Thermo Fisher Scientific in 2025) manufactures and sells specialized capillary membranes under the 3M™ Membrana™ brand for OEM integration into medical devices. The portfolio spans blood oxygenation membranes for cardiac surgery and respiratory therapies, hemodialysis membranes for blood purification, and therapeutic apheresis membranes for plasma separation and fractionation. Products are engineered from synthetic polymers with tailored separation profiles, biocompatibility, and chemical resistance for extracorporeal blood processing devices.
Is 3M a public or private company?
3M is a private company. It is classified as corporate owned and is currently operating.
When was 3M founded?
3M was founded in 2024. It employs 101 to 250 people.
How does 3M make money?
One revenue line is on record: medical Membrane Materials Sales to OEMs.
Who are 3M's main competitors?
Broad incumbents on record are Fresenius Medical Care, Nipro Corporation, Terumo Corporation, Baxter International, Medtronic and B. Braun Avitum. Direct peers are Toray Industries (Medical Division) and Asahi Kasei Medical. Emerging players are Cytiva (Danaher) and Sartorius AG.
Does 3M have an API?
No public API is recorded for 3M.